Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With Hemophilia

ConditionHemophilia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

About this trial

In patients with haemophilia, close monitoring of bleeding with optimal adherence to treatment, a personalised treatment programme and the possibility of early diagnosis of haemarthrosis are essential. The TEMPO project will help advance the state of the art in optimal adherence, rigorous monitoring, and accurate and early diagnosis and management of haemarthrosis by collecting and integrating big data in order to personalise the treatment regimen for each patient, as envisaged by the current model of personalised medicine.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

informed consent

age (minimum 18 years)

hemophilia

having a smartphone

Disqualifiers

autoimmune, inflammatory or degenerative diseases that cause arthritis

Trial design

Design model

Parallel

Treatments tested in this trial

  • TEMPO

    Other intervention

    Personalized telemedicine

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: TEMPOExperimental treatment 1 intervention
Group B: CONTROLNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Veritas Pro score

Score for adherence to prophylactic treatment

Time frame
6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.